NRX Pharmaceuticals, Inc. (NRXP) AI Dilution Summary

NRx had cash of $26,686,000 at 2026-06-30, against estimated monthly burn of $2,195,000. Its active funding channel is an at-the-market program with H.C. Wainwright & Co., LLC, authorised to $20,000,000. The most recent capital raised was a public offering closed 2026-06-04: $22,326,297 gross from 6,378,942 shares at $3.50.